

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

NCT05267886

Status	RECRUITING
Phase	Phase 4
Sponsor	Ottawa Heart Institute Research Corporation
Enrollment	346 participants

Key Eligibility Criteria

Inclusion (2)

- Adult patients e 18 years of age admitted to an intensive care unit
- SCAI class C or D cardiogenic shock

Exclusion (6)

- Unwilling or unable to obtain informed consent by the participant or substitute decision maker
- Patients who are currently pregnant or breast-feeding
- Patients presenting with an out-of-hospital cardiac arrest (OHCA)
- Administration of milrinone or dobutamine in the 24 hours preceding anticipated randomization
- Severe obstructive valvular lesions, including aortic stenosis and/or mitral stenosis

... and 1 more (see full listing online)

Locations (3 total)

Mayo Clinic, Rochester, Minnesota, United States
Hamilton Health Sciences, Hamilton, Ontario, Canada
University of Ottawa Heart Institute, Ottawa, Ontario, Canada